1013-04-3

Basic information

• Product Name: 4-chloro-1-naphthalenecarboxylic acid
• Synonyms: 4-chloro-1-naphthalenecarboxylic acid;4-Chloro-1-naphthoic acid, 98%;4-Chloro-1-napthalenecarboxylic Acid;4-chloro-1-phthalenecarboxylic acid
• CAS NO: 1013-04-3
• Molecular Formula: C₁₁H₇ClO₂
• Molecular Weight: 206.62508
• Mol File: 1013-04-3.mol
• Article Data: 8

Chemical Properties

• Melting Point: 223-224 °C
• Boiling Point: 398.5±15.0 °C(Predicted)
• Appearance: /
• Density: 1.395±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: DMSO (Slightly), Methanol (Slightly, Heated)
• PKA: 3.48±0.10(Predicted)
• CAS DataBase Reference: 4-chloro-1-naphthalenecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-chloro-1-naphthalenecarboxylic acid(1013-04-3)
• EPA Substance Registry System: 4-chloro-1-naphthalenecarboxylic acid(1013-04-3)

Safety Data

• Hazardous Substances Data: 1013-04-3(Hazardous Substances Data)

Usage

Uses

4-Chloro-1-napthalenecarboxylic Acid is used in the synthesis of naphthoyl-indoles as CB1 and CB2 receptor inhibitors.

InChI:InChI=1S/C11H7ClO2/c12-10-6-5-9(11(13)14)7-3-1-2-4-8(7)10/h1-6H,(H,13,14)

Upstream product

• 860539-19-1 1-(4-chloro-[1]naphthyl)-2-phenyl-ethanone 
• 64-19-7 acetic acid 
• 16726-68-4 methyl 4-chloro-1-naphthoate 
• 90-13-1 1-Chloronaphthalene 
• 129667-52-3 4-acetylamino-[1]naphthonitrile 
• 58728-64-6 4-amino-1-naphthonitrile 
• 4053-08-1 p-chloro-1,8-naphthalicanhydride 
• 15719-64-9 methylammonium carbonate 
• 32018-87-4 4-Amino-1-naphthoic acid 
• 22531-53-9 1-acetyl-4-chloronaphthalene 
• 50265-01-5 4-chloro-1-chloromethylnaphthalene 
• 53220-82-9 1-bromo-4-chloronaphthalene 
• 16243-44-0 4-chloro-[1]naphthonitrile 

Downstream Products

• 5471-26-1 4-chloronaphthalenecarbaldehyde 
• 6948-43-2 4-chlor-1-naphthamid 
• 1292765-18-4 JWH-398 
• 1366067-50-6 JWH-397 
• 79996-98-8 1-bromomethyl-4-chloronaphthalene 

Relevant articles and documents

Naphthalene-based poly(aryl ether)s. II. Synthesis and characterization of poly(ether ketone)s containing two 1,4-naphthylene moieties in the repeat unit

Two new monomers, 4-chloro-1-(4′-fluoro-1-naphthoyl)naphthalene and 1,4-bis(4′-fluoro-1′-naphthoyl)benzene, have been synthesized and polymerized with four different bisphenols to give two series of the naphthalene-based poly(ether ketone)s that are analogous to commercial PEEK and PEEKK. The effect of the introduction of one or two 1,4-naphthylene moieties, in the backbone of the repeat unit, on the glass transition temperatures has been studied. The glass transition temperatures usually increased by 20-45°C upon replacing one 1,4-phenylene with one 1,4-naphthylene moiety. All new poly(ether ketone)s prepared in tetramethylene sulfone were amorphous, with the glass transition temperatures in a range of 212-273°C. The polymer produced from 1,4-bis(4′-fluoro-1′-naphthoyl)benzene and 1,4-hydroquinone in phenyl sulfone as a solvent at 300°C showed semicrystalline properties with a melting temperature of 310°C.

The mercury-mediated decarboxylation (Pesci reaction) of naphthoic anhydrides investigated by microwave synthesis

The mercury-mediated decarboxylation (Pesci reaction) of several substituted naphthoic anhydrides has been investigated by microwave synthesis. A laboratory microwave reactor was found to be ideal for small-scale preparations of this slow reaction, reducing reaction times from typically four days to less than 1 h for the three-step process. The ionic reaction medium rapidly heated to high temperatures under microwave heating and could be efficiently maintained by low microwave power settings. Generation of stoichiometric CO2 was safely contained within the reaction tubes. A simplified reaction procedure has been developed. For substituted naphthoic anhydrides, 1H NMR analysis of the naphthoate ester derivatives indicated no change in the regioisomer ratio compared to previously reported thermal values.

Triazole derivative and pharmaceutical use thereof

An agent for the prophylaxis and treatment of immune-related diseases, in particular, immunosuppressant, an agent for the prophylaxis and treatment of allergic diseases, an agent for the prophylaxis and treatment of eosinophil-related diseases and an eosinophilia inhibitor, comprising, as an active ingredient, a series of triazole derivatives of the following formula (I) STR1 or the following formula (III) STR2 wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. A novel monocyclic or bicyclic triazole derivative. The agent for the prophylaxis and treatment of immune-related diseases, in particular, immunosuppressant, the agent for the prophylaxis and treatment of allergic diseases, the agent for the prophylaxis and treatment of eosinophil-related diseases, the eosinophilia inhibitor and the novel triazole derivative of the present invention all, have superior eosinophilia-inhibitory action and lymphocyte activation-inhibitory action. They are low toxic and persistent in action. They are particularly effective in the treatment of accumulation and activation of eosinophil and lymphocytes, inflammatory respiratory tract diseases, eosinophil-related diseases such as eosinophilia, and immune-related diseases.